AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals
pharmafile | April 27, 2016 | News story | Research and Development, Sales and Marketing | AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales
AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted exclusive rights to market gout treatment, Zurampic (lesinurad), in the US.
Ironwood will make an upfront payment of $100 million to acquire exclusive US rights to all products containing lesinurad, which was approved by the FDA in December 2015.
Zurampic was approved for use in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. AstraZeneca plans to submit the fixed-dose combination program of lesinurad for FDA regulatory review by the end of 2016.
Gout is a form of inflammatory arthritis that can be serious, progressive and debilitating. As many as two million patients in the US on urate-lowering therapy remain inadequately controlled, and Zurampic supplements existing treatments to better regulate the condition.
The Massachusetts-based Ironwood will pay AstraZeneca tiered single-digit royalties on product sales as well as sales-related and other milestones of up to $165 million. The London-headquartered company will continue to manufacture and supply the drug.
Tom McCourt, chief commercial officer at Ironwood, says: “This transaction enables Ironwood to leverage our strong commercial capabilities to advance a durable franchise of innovative medicines addressing a significant unmet need in which patients are highly motivated and seeking relief.
“With focused investment into the gout franchise over time, we believe we can maximise cash flows and accelerate our progress as a top-performing commercial biotechnology company: following this transaction, we expect to execute on at least five new launches in the US by 2020, beginning with Zurampic in the second half of 2016 and continuing with, if approved, 72mcg linaclotide in 2017 and a lesinurad-allopurinol fixed-dose combination in 2018.”
The licensing agreement is expected to close in the second quarter of 2016, subject to antitrust approval in the US.
Sean Murray
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
